When folks think of investing, they often think of buying stocks or bonds.

But today, I want to tell you about an investment strategy that doesn't require buying anything. It's not something complicated, difficult to understand, or risky. Instead, it's a way to earn safe, steady income every month. In fact, I've used it for decades, since my time at Goldman Sachs, and it involves two words that terrify many investors...

Selling options.

Now, you might think that selling options is a quick way to lose your shirt. You might have even seen stories of folks making high-risk bets using options in the hopes of huge returns... only to be ruined when the trade almost inevitably goes wrong.

That's not the type of investing I help readers do in my Retirement Trader newsletter...

Unlike most other strategies, though, we "sell" options to earn an income payment up front. In every issue with a new trade, we give readers two ways to make what is essentially the same trade. You can either sell put options or trade covered calls.

Today, we'll keep it simple. So just know that the capital we put up is either used to buy shares up front (as we do for covered calls) or held to cover the obligation that comes with selling puts.

So, what kind of capital do you need to put up? What kind of return can you expect? And how do you keep your capital safe?

That's what we'll talk about here...

When you enter a "covered call" trade, you will need to purchase 100 shares of the given stock. So the capital requirement will be pretty straightforward... It's the cost of 100 shares of stock. Take the stock price and multiply it by 100.

For a stock that trades at $20, that will be $2,000. For a stock that trades at $200, that will be $20,000.

We work to find stocks with low prices, but sometimes we'll recommend trades on higher-priced stocks. (We don't want to keep potentially profitable trades from those who may have larger accounts.)

For a "put sell" trade, you don't need to buy shares up front, but you have a "potential obligation" to buy 100 shares. That means you get to keep that money in your account, but you may need to use it to buy shares in the future. It's still your money for now, but it's what we consider "capital at risk."

On that capital at risk, we expect to earn 3% to 6% on our trades. That does not sound like much, but it adds up big over time...

The power of the Retirement Trader strategy comes not from making one single trade... It comes from making repeated trades, over and over again, and collecting income each time. Over 15 years, we've done it more than 800 times.

Here's how that may work for you...

Let's say we make a trade that takes $10,000 in capital and you earn 3%. That means you collect $300.

If our 94% historical win rate is any guide, the trade is likely a winner and you get to keep your $10,000 and the $300 income payment.

The key is that our Retirement Trader trades are designed to last two months. You collect your money, wait two months, and then close the trade. (At times, we also might "roll" a trade, meaning we keep it going.) But when you close a trade, you can use your $10,000 to put into another trade.

Over the course of a year, you can do this trade six times. That means you can collect about $1,800 on your $10,000... a return of 18%. Plus you'll earn dividends on most of the stocks along the way.

You can't get that anywhere else.

If you want to sell puts, the returns are the same. You don't have to buy shares for $10,000. You can keep the money in cash. But you do have the same amount of capital at risk. You'll earn 3% or so on your capital at risk in either case.

As I mentioned earlier, I've used this strategy for more than 800 trades across 15 years... All with a 95% win rate.

As a result, real Retirement Trader subscribers are using this strategy to generate steady income, month after month.

To celebrate my winning streak – and help readers like you change the way you think about investing – I've put together our best offer yet.

But it closes at midnight tonight. So make sure you get all the details here before it's too late.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team

December 31, 2025

Editor's note: Our offices are closed tomorrow, January 1, for New Year's Day. You'll receive your next issue of the Health & Wealth Bulletin on Friday, January 2. Have a safe and happy new year!

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top